Appeals court upholds $19m Boston Scientific loss in pelvic mesh case

Boston Scientific (NYSE:BSX) has lost another bid as it looked to overturn an $18.5 million loss in a product liability suit over alleged injuries caused by its Obtryx pelvic mesh. A jury in West Virginia federal court in November 2014 found Boston Scientific liable to 4 women following a 10-day trial; the trial judge later ordered the Marlborough, Mass.-based company to pay each of the 4 women damages ranging from $3.25 million to $4.25 million (the 4th plaintiff later settled her case out of court and it was dismissed). In its appeal, Boston Scientific argued that the court’s decision to consolidate the four cases into a single trial created potential prejudice and confusion amongst the jury. The appeals court disagreed, saying that “BSC lacks evidence that the district court’s safeguards were inadequate or that consolidation in fact resulted in any prejudice or jury confusion.” “Instead, it asks us to infer jury confusion based on the similarities of the damages awarded to each plaintiff. Attempting to reverse engineer the jury’s thought processes based on its verdicts is always a dangerous enterprise, because we have no way of knowing what really happened during jury deliberations,” the court wrote, according to official documents. “Here, there is little reason to be suspicious of the verdicts given that BSC had a chance to fully develop its defenses and that the judge properly instructed the jury through...
Source: Mass Device - Category: Medical Devices Authors: Tags: Legal News Product Liability Wall Street Beat Women's Health Boston Scientific Source Type: news

Related Links:

A urinary incontinence drug is surprisingly effective in the treatment of hot flashes for both women with a history of breast cancer and those with menopausal symptoms but who do not have cancer.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Viveve (NSDQ:VIVE) last week priced a follow-on offering worth $20 million. Englewood, Colo.-based Viveve’s eponymous device uses cryogen-cooled monopolar radiofrequency tech designed to treat gynecological conditions. The company said Dec. 6 that it floated 13.3 million shares at $1.50 apiece, for gross proceeds of $20.0 million. The offering includes a 30-day underwriters option on another 2.0 million shares that would reap $3.0 million if fully exercised. The offering is slated to close Dec. 11. Viveve said it plans to use the proceeds to continue commercializing its device, winning further regulatory clearan...
Source: Mass Device - Category: Medical Devices Authors: Tags: Featured Funding Roundup Wall Street Beat Women's Health Viveve Source Type: news
CONCLUSIONS: In elderly patients even with comorbidities, both laparoscopic ventral rectopexy and stapled transanal rectal resection are safe and can improve function of the anorectum in patients with obstructed defecation attributed to structural abnormalities. Laparoscopic ventral rectopexy has better long-term functional outcome, less complications, and less recurrences compared with stapled transanal rectal resection. Perineal descent only improves after laparoscopic ventral rectopexy. Stapled transanal rectal resection was shown not to be the first choice in elderly patients with obstructed defecation unless they ha...
Source: Diseases of the Colon and Rectum - Category: Gastroenterology Tags: Original Contributions Source Type: research
BACKGROUND: Many patients with fecal incontinence report coexisting constipation. This subset of patients has not been well characterized or understood. OBJECTIVE: The purpose of this study was to report the frequency of fecal incontinence with concurrent constipation and to compare quality-of-life outcomes of patients with fecal incontinence with and without constipation. DESIGN: This was a prospective cohort study. Survey data, including Fecal Incontinence Severity Index, Constipation Severity Instrument, Fecal Incontinence Quality of Life survey (categorized as lifestyle, coping, depression, and embarrassment), ...
Source: Diseases of the Colon and Rectum - Category: Gastroenterology Tags: Original Contributions Source Type: research
CONCLUSIONS: Composite graft in patients with intractable fecal incontinence can serve as a viable novel method for total anorectal reconstruction. However, it should only be recommended for a highly select group of individuals in a surveillance setting. Its long-term outcomes remain to be determined as well as its risk versus benefit.
Source: Diseases of the Colon and Rectum - Category: Gastroenterology Tags: Dynamic Article Source Type: research
Discussions were transcribed verbatim and analyzed using descriptive content analysis. RESULTS: The rate of incontinence among audited patients (N= 259, 132 men, 124 women; mean age 73.2 ± 16.8 years) was 47.2% (119/252) and 2/259 (0.8%) had a pressure injury (PI). IAD prevalence was significantly lower in the post- than in the pre-implementation audit (6/259 vs 23/250, P = .015), as was hospital-acquired pressure injury (9/250 [3.6%] vs 2/259 [0.08%]) and the use of bed protection layers (154/238 vs 6/259; P
Source: Ostomy Wound Management - Category: Surgery Tags: Ostomy Wound Manage Source Type: research
A familiar drug for urinary incontinence has been found to reduce hot flashes in women after breast cancer.
Source: WebMD Health - Category: Consumer Health News Source Type: news
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Gynecology, Oncology, Pharmacy, News, Source Type: news
FRIDAY, Dec. 7, 2018 -- Hot flashes, a common curse in menopause, can be especially bothersome after breast cancer. But a new study suggests an existing medication may help. The drug is oxybutynin (Ditropan XL), long used to treat urinary...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
FRIDAY, Dec. 7, 2018 -- Hot flashes, a common curse in menopause, can be especially bothersome after breast cancer. But a new study suggests an existing medication may help. The drug is oxybutynin (Ditropan XL), long used to treat urinary...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
More News: Incontinence | Legislation | Women